Brief: Redx Pharma Announces RXC004 Topline Data From a Phase 2 Monotherapy Module

Redx Pharma

08/03/2023 08:11

March 8 (Reuters) - Redx Pharma PLC  REDX.L :
    * REDX PHARMA PLC - RXC004 TOPLINE DATA FROM A PHASE 2
MODULE
    * REDX PHARMA PLC - OVERALL EFFICACY RESULTS NOT SUFFICIENT
TO
SUPPORT FURTHER DEVELOPMENT AS A MONOTHERAPY IN ADVANCED BILIARY
TRACT CANCER PATIENTS
    * REDX PHARMA PLC - TOP-LINE DATA FROM COMBINATION TREATMENT
MODULES EXPECTED IN H2 2023

Source text for Eikon:  ID:nRSH2221Sa 
Further company coverage:  REDX.L 

 ((Reuters.Briefs@thomsonreuters.com;))